Maria Chiara Decaroli

Maria Chiara Decaroli

Auto-generated profile, based on publicly available information

Maria Chiara Decaroli

Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2022 in The Aging Male
Verified
Journal Article
Open access
SVSara De Vincentis
Sara De Vincentis
MDMaria Chiara Decaroli
Maria Chiara Decaroli
FFFlaminia Fanelli
Flaminia Fanelli
CDChiara Diazzi
Chiara Diazzi
MMMarco Mezzullo
Marco Mezzullo
VRVincenzo Rochira
Vincenzo Rochira
Data about classification of hypogonadism and estrogen deficiency in male people living with HIV (PLWH) are scanty.To investigate the prevalence and characterization of biochemical hypogonadism and...

12 January 2023 in Andrology
Verified
Journal Article
Open access
SVSara De Vincentis
Sara De Vincentis
MDMaria Chiara Decaroli
Maria Chiara Decaroli
JMJovana Milic
Jovana Milic
FFFlaminia Fanelli
Flaminia Fanelli
GTGiulia Tartaro
Giulia Tartaro
VRVincenzo Rochira
Vincenzo Rochira
Background: Sexual dysfunctions, particularly erectile dysfunction, are common in men living with HIV, whose organic and psychological components remain to be clarified. The aim of the study is to investigate the impact of risk factors of sexual dysfunctions, including organic, relational, and psychological determinants of erectile function, in men living with HIV younger than 50 years old.Methods: A cross‐sectional, observational study was conducted in men living with HIV < 50 years. The questionnaire International Index of Erectile Function‐15 was used to assess the prevalence and degree of erectile dysfunction. The structured interview of erectile dysfunction was used to explore the organic (Scale 1), relational (Scale 2), and psychological (Scale 3) components of erectile dysfunction. Total testosterone, estradiol, and dihydrotestosterone were measured by liquid chromatography‐tandem‐mass spectrometry; free testosterone was calculated by the Vermeulen equation.Results: A total of 313 consecutive men living with HIV were prospectively enrolled (median age 47.0 years; median HIV‐infection duration 16.2 years). 187 patients (59.7%) had erectile dysfunction, with a higher prevalence of non‐heterosexual (138 out of 187, 73.8%) than heterosexual patients (p = 0.003). Patients with erectile dysfunction showed a worse score of structured interview of erectile dysfunction scale 3 compared to patients without erectile dysfunction (p = 0.025); the International Index of Erectile Function‐15 was inversely related to structured interview of erectile dysfunction scale 3 (p = 0.042). No difference was found for sex steroids (total testosterone, estradiol, free testosterone, and dihydrotestosterone) between men living with HIV with and without erectile dysfunction. In the multivariate analysis sexual orientation, and lack of stable relationships were major determinants for erectile dysfunction. Only 35 of 187 patients with erectile dysfunction (18.7%) reported the use of erectile dysfunction medications.Conclusions: Within the multidimensional network of erectile dysfunction in men living with HIV, the psychological component is predominant, highlighting the contribution of peculiar factors related to HIV distress (e.g., fear of virus transmission, stigma) rather than gonadal status and other classical risk factors. In contrast to the high prevalence, only a few patients reported the use of erectile dysfunction medications suggesting a general under‐management of such issues.

20 April 2024 in Journal of Endocrinological Investigation
Verified
Journal Article
Open access
PDF file
SVS De Vincentis
S De Vincentis
CGCarla Greco
Carla Greco
FFFlaminia Fanelli
Flaminia Fanelli
MDM C Decaroli
M C Decaroli
CDC Diazzi
C Diazzi
VRVincenzo Rochira
Vincenzo Rochira
Purpose: Sex steroids play a key role on male bone homeostasis and body composition (BC), their role in men living with HIV (MLWH) is less recognized. This study aimed at investigating the prevalence of low BMD, sarcopenia, and sarcopenic obesity (SO) and their relationship with sex steroids in MLWH aged < 50. Methods: Prospective, cross-sectional, observational study on MLWH younger than 50 (median age 47.0 years). BC and BMD were evaluated with DXA. Two different definitions of sarcopenia were applied: appendicular lean mass/height2 (ALMI) < 7.26 kg/m2 or appendicular lean mass/body weight (ALM/W) < 28.27%. Low BMD was defined for Z-score < −2.0. Sarcopenia coupled with obesity identified SO. Serum total testosterone (T) and estradiol (E2) were measured by LC–MS/MS; free testosterone (cFT) was calculated by Vermeulen equation. Results: Sarcopenia was detected in 107 (34.9%) and 44 (14.3%) out of 307 MLWH according to ALMI and ALM/W, respectively. The prevalence of SO was similar by using both ALMI (11.4%) and ALM/W (12.4%). Sarcopenic and SO MLWH had lower total T and cFT in both the definition for sarcopenia. BMD was reduced in 43/307 (14.0%). Serum E2 < 18 pg/mL was an independent contributing factor for sarcopenia, SO, and low BMD. Conclusions: T and E2 are important determinants of BC even in MLWH. This is among the first studies investigating the distribution of obesity phenotypes and the prevalence of SO among MLWH showing that SO is present in 11–12% of enrolled MLWH regardless of the definition used. However, deep differences emerged using two different diagnostic definitions.

10 April 2021 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
MDMaria Chiara Decaroli
Maria Chiara Decaroli
AAAnna Ansaloni
Anna Ansaloni
MMMaria Laura Monzani
Maria Laura Monzani
MLMarco Losa
Marco Losa
EZElena Zunarelli
Elena Zunarelli
BMBruno Madeo
Bruno Madeo
Background Temozolomide (TMZ) is safe and effective in the treatment of aggressive pituitary adenomas (PAs). However, the optimal duration of TMZ therapy is still unknown. Moreover, data about administration of TMZ in elderly (≥65 years) people to treat aggressive PAs are scarce. We report the case of the oldest female patient undergoing the longest TMZ protocol described so far to treat an aggressive, initially silent corticotroph PA. Case report The patient initially underwent partial surgical removal of the PA. Subsequent treatment with cabergoline was applied, but it was unsuccessful in controlling the growth of the residual tumor. Pasireotide and external radiation also showed to be ineffective; therefore, treatment with TMZ was started at the standard dose of 200 mg/m2/day for 5 days every 4 weeks for a total of 47 cycles. At the time of treatment’s beginning, the patient was 83 years old. Radiological follow-up documented a progressive, remarkable reduction of the adenoma and the last imaging, after 39 cycles of TMZ, showed an intrasellar lesion with large areas of cystic degeneration. The patient also developed adrenal deficiency managed with glucocorticoid replacement. No major side effects were observed throughout the treatment, with exception of nausea, well controlled with anti-emetic medication. TMZ therapy was discontinued after 47 cycles; hormonal and imaging follow-up investigations documented sustained functional and dimensional response. Conclusions Our case supports the long-term use of TMZ, confirming its safety and efficacy also for elderly patients.

1 May 2019 in Endocrine Abstracts
Verified
Journal Article
Open access
VDVincentis Sara De
Vincentis Sara De
MDMaria Chiara Decaroli
Maria Chiara Decaroli
FFFlaminia Fanelli
Flaminia Fanelli
MMMarco Mezzullo
Marco Mezzullo
CDChiara Diazzi
Chiara Diazzi
VRVincenzo Rochira
Vincenzo Rochira
Background: HIV-infection is associated to premature decline of serum T. However, prevalence and biochemical characterization of hypogonadism in HIV-infected men are still to be well defined. Aim: To evaluate the gonadal status in HIV-infected men by assessing circulating total T (TT) with either ID-LC-MS/MS or CI. Methods: Prospective, cross-sectional, observational study on HIV-infected men with ongoing Highly Active Antiretroviral Therapy (HAART). Serum TT, gonadotropins and sex hormone-binding globulin (SHBG) were measured by CI (Architect, Abbott, USA). TT was also assessed by a validated in house ID-LC-MS/MS. Free T (FT) was calculated by Vermeulen equation. Hypogonadism was defined as serum TT levels below 320 ng/dl and/or free T levels below 64 pg/ml. Statistical analysis: Parameters were not normally distributed and Mann-Whitney U test, was used to compare continuous variables. Categorical variables were compared using Chi-Square test, while correlations were performed using linear regression models. Results: 315 consecutive HIV-infected men were enrolled (mean age 45.56±5.61 years; average duration of HIV-infection 16.57±10.45 years). Serum TT levels assessed by LC-MS/MS (mean 652.1+229.1 ng/dl) were significantly lower compared to CI (mean 740.2+274.7 ng/dl) (P<0.0001). As a consequence, prevalence of T deficiency was significantly higher comparing LC-MS-MS to CI (5.4% vs 3.2%, P71.4 nmol/l). Considering calculated FT, the prevalence of hypogonadism was 9.8% using LC-MS/MS and 7.0% using CI, with a significant difference between methodologies (P<0.0001). TT assessed with LC-MS-MS was directly related to TT assessed with CI (Beta=0.956, R2=0.913, P<0.0001), as well as FT (Beta=0.934, R2=0.873, P<0.0001). TT combined with luteinizing hormone (LH) levels was used to classify hypogonadism. By including compensated form of hypogonadism, the prevalence raised to 15.6% for TT and to 17% for FT. Conclusions: To the best of our knowledge, this is the first properly-designed prospective study aiming to investigate the gonadal status of HIV-infected men with both LC-MS/MS and CI, together with gonadotropins. Notwithstanding the strong correlation found between the two methodologies, the prevalence of hypogonadism results underestimated when CI is used compared to ID-LC-MS/MS in HIV-infected patients. In clinical practice, SHBG for calculated FT is essential for the detection of T deficiency, revealing the real prevalence of hypogonadism in this clinical setting.